---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-097730"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2023-09-01T23:59:59+00:00"
generated_at: "2026-06-11T00:42:15.434967+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "low"
source: SEC EDGAR
---

# TriSalus Life Sciences furnishes September 2023 investor slide deck; no material new information disclosed

## Summary
- Slide deck posted on company website for investor use; no earnings, guidance, or corporate updates provided.
- Presentation reiterates mission to treat liver and pancreatic tumors through immunotherapy and drug delivery technology.
- No changes in financial position, operations, or management disclosed; filing is routine Regulation FD disclosure.

## SEC filing metadata
- accession: 0001104659-23-097730
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2023-09-01T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465923097730/0001104659-23-097730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465923097730/tm2325342d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-097730
- JSON: https://secwatch.observer/filing/0001104659-23-097730.json
- Plain text: https://secwatch.observer/filing/0001104659-23-097730.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.